Reviewer's report

Title: Case report: Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion

Version: 0 Date: 26 Mar 2016

Reviewer: Thomas Friberg

Reviewer's report:

The paper describes a rare but plausible event after the injection of an anti-vegf, the precipitation of an angle closure attack. It may be the first case described, but it always dangerous to aver that this is so. "likely the first description or may be the first description" would be better. Also, the consideration that volume of the eye being injected is so important may not be true. The key element is ocular rigidity, and though volume of the recipient globe may be an important variable, it turns out that buckled eyes, for instance, are less likely to show a pressure rise from an injection than an unbuckled eye, yet the volume of an eye that has been scleral buckled is less than in the unbuckled state. See Friberg TR and Fourman SB: Scleral buckling and ocular rigidity: Clinical ramifications. Arch Ophthalmol. 108:1622-1627, 1990.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal